RANDOMIZED, PHASE II/III TWO-ARMED STUDY OF AT/A2

AT/A2 的随机、II/III 期双臂研究

• 批准号: 6244886
• 负责人: FRANK GIGLIOTTI
• 金额: $ 2.02万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-14 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6244886
• 关键词: HIV infections; adolescence (12-20); antiAIDS agent; atovaquone; azithromycin; bacterial disease; clinical research; combination chemotherapy; disease /disorder prevention /control; human subject; human therapy evaluation; middle childhood (6-11); pediatric AIDS; preschool child (1-5); thymidine monophosphate

This is a phase II/III, double-blind, multi-centered, placebo controlled, two-armed study comparing atovaquone and azithromycin to TMP/SMX in the prevention of serious bacterial infections when used in children 2-18 years of age with HIV infection.

这是一项II/III期、双盲、多中心、安慰剂研究 阿托伐醌和阿奇霉素的对照、双臂研究 TMP/SMX用于预防严重细菌感染时 2-18岁感染艾滋病毒的儿童。